Cargando…

Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Yi-Giien, Liao, Pei-Fen, Hsiao, Kai-Hung, Wu, Hung-Ming, Lin, Ching-Yuang, Yang, Kuender D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522836/
https://www.ncbi.nlm.nih.gov/pubmed/37771588
http://dx.doi.org/10.3389/fimmu.2023.1230264
_version_ 1785110436492869632
author Tsai, Yi-Giien
Liao, Pei-Fen
Hsiao, Kai-Hung
Wu, Hung-Ming
Lin, Ching-Yuang
Yang, Kuender D.
author_facet Tsai, Yi-Giien
Liao, Pei-Fen
Hsiao, Kai-Hung
Wu, Hung-Ming
Lin, Ching-Yuang
Yang, Kuender D.
author_sort Tsai, Yi-Giien
collection PubMed
description Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE.
format Online
Article
Text
id pubmed-10522836
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105228362023-09-28 Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus Tsai, Yi-Giien Liao, Pei-Fen Hsiao, Kai-Hung Wu, Hung-Ming Lin, Ching-Yuang Yang, Kuender D. Front Immunol Immunology Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE. Frontiers Media S.A. 2023-09-12 /pmc/articles/PMC10522836/ /pubmed/37771588 http://dx.doi.org/10.3389/fimmu.2023.1230264 Text en Copyright © 2023 Tsai, Liao, Hsiao, Wu, Lin and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tsai, Yi-Giien
Liao, Pei-Fen
Hsiao, Kai-Hung
Wu, Hung-Ming
Lin, Ching-Yuang
Yang, Kuender D.
Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus
title Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus
title_full Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus
title_fullStr Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus
title_full_unstemmed Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus
title_short Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus
title_sort pathogenesis and novel therapeutics of regulatory t cell subsets and interleukin-2 therapy in systemic lupus erythematosus
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522836/
https://www.ncbi.nlm.nih.gov/pubmed/37771588
http://dx.doi.org/10.3389/fimmu.2023.1230264
work_keys_str_mv AT tsaiyigiien pathogenesisandnoveltherapeuticsofregulatorytcellsubsetsandinterleukin2therapyinsystemiclupuserythematosus
AT liaopeifen pathogenesisandnoveltherapeuticsofregulatorytcellsubsetsandinterleukin2therapyinsystemiclupuserythematosus
AT hsiaokaihung pathogenesisandnoveltherapeuticsofregulatorytcellsubsetsandinterleukin2therapyinsystemiclupuserythematosus
AT wuhungming pathogenesisandnoveltherapeuticsofregulatorytcellsubsetsandinterleukin2therapyinsystemiclupuserythematosus
AT linchingyuang pathogenesisandnoveltherapeuticsofregulatorytcellsubsetsandinterleukin2therapyinsystemiclupuserythematosus
AT yangkuenderd pathogenesisandnoveltherapeuticsofregulatorytcellsubsetsandinterleukin2therapyinsystemiclupuserythematosus